S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.36%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Actualizaciones en tiempo real para Catalyst Pharmaceuticals [CPRX]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
BUY
83.33%
return 4.42%
SELL
33.33%
return 3.66%
Última actualización26 abr 2024 @ 16:00

1.43% $ 14.89

COMPRAR 106561 min ago

@ $13.37

Emitido: 14 feb 2024 @ 14:08


Retorno: 11.41%


Señal anterior: feb 13 - 10:35


Señal anterior: Vender


Retorno: 0.00 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States...

Stats
Volumen de hoy 772 159
Volumen promedio 1.34M
Capitalización de mercado 1.75B
EPS $0 ( 2024-03-20 )
Próxima fecha de ganancias ( $0.340 ) 2024-05-08
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E 23.63
ATR14 $0.00800 (0.05%)
Insider Trading
Date Person Action Amount type
2024-04-08 Tierney David S Buy 25 000 Common stock, par value $0.001 per share
2024-04-08 Tierney David S Sell 25 000 Common stock, par value $0.001 per share
2024-04-08 Tierney David S Buy 25 000 Options to purchase common stock
2024-03-27 Elsbernd Brian Sell 25 000 Common stock, par value $0.001 per share
2024-02-15 Del Carmen Jeffrey Sell 10 667 Restricted Stock Units
INSIDER POWER
37.04
Last 100 transactions
Buy: 3 182 900 | Sell: 1 448 545

Volumen Correlación

Largo: -0.46 (neutral)
Corto: -0.52 (weak negative)
Signal:(47.337) Neutral

Catalyst Pharmaceuticals Correlación

10 Correlaciones Más Positivas
PMTS0.897
KPTI0.88
AVID0.873
PRAA0.854
FCCO0.852
BNIXU0.849
PINC0.848
KTCC0.844
PARA0.843
DTEA0.838
10 Correlaciones Más Negativas
CVGI-0.927
CRSP-0.915
NNOX-0.915
POWL-0.914
ADMS-0.914
FTDR-0.912
MDXG-0.912
FLGC-0.905
CNCE-0.905
RESN-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Catalyst Pharmaceuticals Correlación - Moneda/Commodity

The country flag -0.48
( neutral )
The country flag -0.30
( neutral )
The country flag 0.00
( neutral )
The country flag -0.51
( weak negative )
The country flag 0.00
( neutral )
The country flag 0.77
( moderate )

Catalyst Pharmaceuticals Finanzas

Annual 2023
Ingresos: $398.20M
Beneficio Bruto: $313.67M (78.77 %)
EPS: $0.670
FY 2023
Ingresos: $398.20M
Beneficio Bruto: $313.67M (78.77 %)
EPS: $0.670
FY 2022
Ingresos: $214.20M
Beneficio Bruto: $179.81M (83.94 %)
EPS: $0.800
FY 2021
Ingresos: $140.83M
Beneficio Bruto: $118.95M (84.46 %)
EPS: $0.380

Financial Reports:

No articles found.

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico